B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

63.42 -2.18 (-3.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biomarin Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
Via Benzinga
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
NASDAQ:BMRN is not too expensive for the growth it is showing.
While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable. 
Via Chartmill
$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
BioMarin Pharmaceutical shifts focus to commercial operations for Roctavian in the U.S., Germany, and Italy. Projected cost reductions aim to achieve profitability by 2025. Strong Q2 performance driven... 
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock which is not overvalued. 
Via Chartmill
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
Via Benzinga
Peering Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Via Benzinga
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Via Benzinga
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Via Benzinga
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Looking Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
NASDAQ:BMRN is not too expensive for the growth it is showing.
Looking for growth without the hefty price tag? Consider BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN). 
Via Chartmill
Analyst Ratings For Biomarin Pharmaceutical
Via Benzinga
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced. 
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable. 
Via Chartmill
CrowdStrike, KKR, GoDaddy To Join S&P 500 In Quarterly Rebalance; Stocks Jump
KKR and GoDaddy also will join before the open on June 24. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
BridgeBio stock rallies on upbeat study results of a drug for a genetic disease that affects the limbs and spine. 
Via Investor's Business Daily
Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)
Last week, these 10 large-cap stocks had the worst performance. NICE, PBR, FIX, LI, MLM, VMC, BMRN, EDU, GFI, MUFG all saw significant decreases. 
Via Benzinga
4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Plain-as-day bargains can still be found, even with the innovation-fueled Nasdaq Composite powering to a fresh all-time high. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The 3 Best Biotech Stocks to Buy in May 2024
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May. 
Via InvestorPlace
Citi Just Cut Its Price Target on These 3 Stocks
Reviewing analyst downgrades may help safeguard investment portfolios amid market uncertainty and Citi price target cuts. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.